NIAID is committed to advancing the understanding of how and why autoimmune diseases such as rheumatoid arthritis (RA) occur and to conduct clinical research studies to develop more effective treatment approaches and prevention strategies.

Anti-TNF Agents for the Treatment of Rheumatoid Arthritis (ClinicalTrials.gov identifier NCT00837434)
The primary purpose of this study is to determine the effectiveness of two tumor necrosis factor (TNF) inhibitors, etanercept and adalimumab, on memory B lymphocytes (B cells) in the peripheral blood of participants with RA.

Read about Living with Arthritis by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS).